

*

B-11

File U S Pub Heal

Copy of notice sent to recipients of
U.S.P.H Grants

Charlie

In consideration of my employment by The Regents of
 The University of Wisconsin in connection with work which has been
 conducted or may hereafter be conducted in the performance of
 grant made by the United States Department of Health, Education,
 and Welfare, Public Health Service, National Institutes of Health
 (hereinafter referred to as the Grantor), identified as Grant
 No. _____, and any continuation or supplement thereto,
 to The Regents of The University of Wisconsin (hereinafter referred
 to as the University), and in accordance with the terms of said
 grant I hereby agree to refer promptly to the University (Office
 of Vice President of Business and Finance) any patentable dis-
 coveries or inventions arising out of the work aided by the above
 grant in order that the University may report the matter to the
 Grantor (Division of Research Grants, Public Health Service) for
 determination by the Surgeon General whether such patentable dis-
 coveries or inventions shall be patented and the manner of ob-
 taining and disposing of the proposed patents in order to protect
 the public interest, and I hereby agree to be bound by said
 determination.

IN WITNESS WHEREOF, I have hereunto set my hand this

_____ day of _____ 19 ____.

WITNESS:

Signed



Invention

Warfarin

Inventor

Karl Paul Link

Period of Exclusivity

Nonexclusive

Royalty Rate

Based on about 1.5% of the wholesale selling price of rodenticide formulation sold to retail outlets. (This translates to about 31% of the selling price of the active chemical ingredient which is used at the rate of 250 parts per million in the finished baits.)*

Performance Requirement

Licensee must use best efforts to satisfy demand.

Control

Products must be approved by Foundation.

*Note:

Consider giving information on the average selling price and corresponding royalty instead of including this parenthetical statement.

Invention

Warfarin

Inventor

Karl Paul Link

Period of Exclusivity

Nonexclusive

Royalty Rate

Based on about 1.5% of the wholesale selling price of rodenticide formulation sold to retail outlets. (This translates to about 31% of the selling price of the active chemical ingredient which is used at the rate of 250 parts per million in the finished baits.)*

Performance Requirement

Licensee must use best efforts to satisfy demand.

Control

Products must be approved by Foundation.

*Note:

Consider giving information on the average selling price and corresponding royalty instead of including this parenthetical statement.

Invention

Warfarin

Inventor

Karl Paul Link

Period of Exclusivity

Nonexclusive

Royalty Rate

Based on about 1.5% of the wholesale selling price of rodenticide formulation sold to retail outlets. (This translates to about 31% of the selling price of the active chemical ingredient which is used at the rate of 250 parts per million in the finished baits.)*

Performance Requirement

Licensee must use best efforts to satisfy demand.

Control

Products must be approved by Foundation.

*Note:

Consider giving information on the average selling price and corresponding royalty instead of including this parenthetical statement.